Loading..

Sutro Biopharma, Inc. (STRO) Report Analysis

Corporate Events

Neutral

Astellas and Sutro Biopharma Announce Worldwide...

2022-06-27 23:30:00

Astellas Pharma Inc. and Sutro Biopharma, Inc. announced a worldwide, strategic collaboration and licensing agreement focused on the discovery...

Negative

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped fr...

2022-06-24 00:00:00

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell Small Cap Comp Growth Index

Negative

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped fr...

2022-06-24 00:00:00

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell 3000 Growth Index

Negative

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped fr...

2022-06-24 00:00:00

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell 2000 Growth Index

Negative

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped fr...

2022-06-24 00:00:00

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell 3000E Growth Index

Negative

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped fr...

2022-06-24 00:00:00

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell Microcap Growth Index

Negative

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped fr...

2022-06-24 00:00:00

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell 2500 Growth Index

Negative

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped fr...

2022-06-11 00:00:00

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from S&P Biotechnology Select Industry Index

Neutral

Sutro Biopharma, Inc. Presents at 2022 Jefferie...

2022-05-19 05:18:00

Sutro Biopharma, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 08:00 AM. Venue: Marriott Marquis, New York City, N...

Neutral

Sutro Biopharma, Inc. Presents at Berenberg Eme...

2022-05-12 11:59:00

Sutro Biopharma, Inc. Presents at Berenberg Emerging Biotech Conference 2022, May-19-2022 .

Neutral

Sutro Biopharma, Inc. Presents at The JMP Secur...

2022-05-02 15:24:00

Sutro Biopharma, Inc. Presents at The JMP Securities Life Sciences Conference 2022, Jun-16-2022 09:30 AM. Venue: Lotte New York Palace, 455 Ma...

Neutral

Sutro Biopharma, Inc. - Shareholder/Analyst Call

2022-04-25 10:05:00

AGM

Neutral

Sutro Biopharma, Inc., Annual General Meeting, ...

2022-04-25 10:05:00

Sutro Biopharma, Inc., Annual General Meeting, Jun 06, 2022, at 08:00 Pacific Standard Time. Agenda: To elect four Class I directors, each to ...

Neutral

Sutro Biopharma, Inc. Presents at PEGS Boston C...

2022-04-23 07:37:00

Sutro Biopharma, Inc. Presents at PEGS Boston Conference 2022, May-05-2022 09:00 AM. Venue: Boston, Massachusetts, United States. Speakers: Ar...

Positive

Sutro Biopharma, Inc. Presents Nonclinical Data...

2022-04-08 17:00:00

Sutro Biopharma, Inc. announced new nonclinical data for its folate receptor alpha (FolRa) targeting antibody-drug conjugate (ADC) STRO-002, i...

Neutral

Sutro Biopharma, Inc. Presents at AACR Annual M...

2022-04-08 16:09:00

Sutro Biopharma, Inc. Presents at AACR Annual Meeting 2022, Apr-08-2022 12:00 PM. Venue: Ernest N. Morial Convention Center, New Orleans, Loui...

Neutral

Joh. Berenberg, Gossler & Co. KG, Berenberg Eme...

2022-04-08 04:47:00

Joh. Berenberg, Gossler & Co. KG, Berenberg Emerging Biotech Conference 2022, May 19, 2022.

Neutral

Sutro Biopharma, Inc. Presents at World ADC Eur...

2022-04-01 16:18:00

Sutro Biopharma, Inc. Presents at World ADC Europe 2022, Mar-29-2022 through Apr-01-2022. Presentation Date & Speakers: Mar-29-2022, Trevor J....

Neutral

Sutro Biopharma, Inc. Presents at 12th Annual W...

2022-03-30 09:20:00

Sutro Biopharma, Inc. Presents at 12th Annual World ADC Conference 2022, Mar-29-2022 through Mar-31-2022. Venue: London, United Kingdom. Prese...

Neutral

Sutro Biopharma, Inc. Presents at Wells Fargo A...

2022-03-29 20:00:00

Sutro Biopharma, Inc. Presents at Wells Fargo Annual Biotech Forum, Apr-12-2022 . Venue: Miami, Florida, United States. Speakers: Annie J. Cha...

Neutral

Hanson Wade Limited, 12th Annual World ADC Con...

2022-03-29 17:52:00

Hanson Wade Limited, 12th Annual World ADC Conference 2022, Mar 29, 2022 through Mar 31, 2022. Venue: London, United Kingdom.

Neutral

Wells Fargo Securities, LLC, Wells Fargo Annual...

2022-03-29 11:02:00

Wells Fargo Securities, LLC, Wells Fargo Annual Biotech Forum, Apr 12, 2022 through Apr 13, 2022. Venue: Miami, Florida, United States.

Neutral

Sutro Biopharma, Inc. Presents at Needham 21st ...

2022-03-04 13:30:00

Sutro Biopharma, Inc. Presents at Needham 21st Annual Healthcare Conference, Apr-14-2022 03:00 PM. Speakers: Bill Newell, Chief Executive Officer.

Neutral

JMP Securities LLC, the JMP Securities Life Sci...

2022-02-16 16:45:00

JMP Securities LLC, The JMP Securities Life Sciences Conference 2022, Jun 15, 2022 through Jun 16, 2022. Venue: Lotte New York Palace, 455 Mad...

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare...

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New Yor...

Neutral

Needham & Company, LLC, Needham 21st Annual Hea...

2022-02-11 23:04:00

Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022.

Neutral

American Association For Cancer Research, AACR ...

2022-01-13 18:45:00

American Association For Cancer Research, AACR Annual Meeting 2022, Apr 08, 2022 through Apr 14, 2022. Venue: Ernest N. Morial Convention Cent...

Neutral

Cambridge Innovation Institute, LLC, PEGS Bosto...

2022-01-13 18:45:00

Cambridge Innovation Institute, LLC, PEGS Boston Conference 2022, May 02, 2022 through May 06, 2022. Venue: Boston, Massachusetts, United States.

Neutral

Sutro Biopharma, Inc. Enters into Licensing Agr...

2021-12-27 12:01:00

On December 24, 2021, Sutro Biopharma, Inc. entered into a licensing agreement with Tasly Biopharmaceuticals Co., Ltd. (“ Tasly ”), to grant T...

Neutral

Sutro Biopharma, Inc. - Special Call

2021-12-27 12:00:00

To Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program STRO-002 for Treatment of Advanced Ovarian Cancer

Neutral

Sutro Biopharma and Tasly Biopharmaceuticals En...

2021-12-27 12:00:00

Sutro Biopharma, Inc. announced an exclusive license agreement with Tasly Biopharmaceuticals Co. Ltd. for the development and commercializatio...

Positive

Sutro Biopharma, Inc. Announces Company Kol Vir...

2021-12-27 12:00:00

Sutro Biopharma, Inc. announced that it will provide interim data from the Company's ongoing dose-expansion cohort of the Phase 1 study of STR...

Positive

Fred Hutchinson Cancer Research Center, in Part...

2021-12-13 12:00:00

Sutro Biopharma, Inc. announced that its research collaborators at the Fred Hutchinson Cancer Research Center presented nonclinical data of ST...

Neutral

Sutro Biopharma, Inc. Presents at Piper Sandler...

2021-11-22 15:06:00

Sutro Biopharma, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.

Neutral

Sutro Biopharma, Inc. Presents at Piper Sandler...

2021-11-19 20:08:00

Sutro Biopharma, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM. Speakers: Bill...

Negative

Sutro Biopharma, Inc. Announces Appointment of ...

2021-11-17 12:00:00

Sutro Biopharma, Inc. announced that Heidi Hunter has been appointed to the company's Board of Directors. Heidi Hunter has over 25 years of ex...

Neutral

Hanson Wade Limited, World ADC Europe 2022, Mar...

2021-11-09 17:12:00

Hanson Wade Limited, World ADC Europe 2022, Mar 29, 2022 through Apr 01, 2022.

Neutral

Piper Sandler Companies, Piper Sandler 33rd Ann...

2021-10-25 10:00:00

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.

Neutral

Sutro Biopharma, Inc. Presents at 4th Annual Ev...

2021-10-22 14:50:00

Sutro Biopharma, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 10:05 AM. Speakers: Bill Newell, Chief Ex...

Neutral

Sutro Biopharma, Inc. Presents at 12th Annual J...

2021-10-21 02:25:00

Sutro Biopharma, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom. Spe...

Neutral

Sutro Biopharma and BioNova Pharmaceuticals Ent...

2021-10-12 11:00:00

Sutro Biopharma, Inc. and BioNova Pharmaceuticals Limited jointly announced an option agreement for BioNova to develop and commercialize STRO-...

Neutral

Sutro Biopharma, Inc. Presents at 30th Annual C...

2021-10-01 10:34:00

Sutro Biopharma, Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-10-2021 04:20 PM. Venue: Rancho Palos Verdes, Californi...

Neutral

Sutro Biopharma Announces Extension of Cytokine...

2021-09-30 11:00:00

Sutro Biopharma, Inc. announced that Merck, known as MSD outside the United States and Canada, has extended the research term for the first cy...

Neutral

Sutro Biopharma, Inc. Presents at Stifel 2021 V...

2021-09-28 21:20:00

Sutro Biopharma, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-15-2021 01:20 PM. Venue: New York, New York, United States. S...

Negative

Sutro Biopharma, Inc. Announces Management Changes

2021-09-16 11:00:00

Sutro Biopharma, Inc. announced the appointment of two executives to the company's leadership team. Nicole M. Chieffo, MBA, has joined as Vice...

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCO...

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Positive

Sutro Biopharma, Inc. Announces STRO-002 FDA Fa...

2021-08-18 11:00:00

Sutro Biopharma, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for STRO-002, a folate rec...

Negative

Sutro Biopharma, Inc. Announces the Appointment...

2021-08-09 11:00:00

Sutro Biopharma, Inc. announced the appointment of Jane Chung to the newly-created position of Chief Commercial Officer, effective August 9, 2...

Neutral

Sutro Biopharma, Inc. has filed a Shelf Registr...

2021-08-06 00:00:00

Sutro Biopharma, Inc. has filed a Shelf Registration in the amount of $13.905 million. Security Name: Common Stock Securities Offered: 750...

Neutral

Sutro Biopharma, Inc. Presents at Wells Fargo 2...

2021-07-22 14:24:00

Sutro Biopharma, Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-09-2021 03:20 PM. Speakers: William J. Newell, CEO & Director.

Neutral

Wells Fargo Securities, LLC, Wells Fargo 2021 V...

2021-07-22 09:08:00

Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021.

Neutral

Stifel, Nicolaus & Company, Incorporated, Stife...

2021-07-08 08:44:00

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New ...

Neutral

Wedbush Securities Inc., 12th Annual Wedbush Pa...

2021-06-29 20:28:00

Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021.

Neutral

Sutro Biopharma, Inc. Presents at 12th Annual W...

2021-06-29 20:28:00

Sutro Biopharma, Inc. Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-11-2021 02:20 PM. Speakers: William J. Newell...

Neutral

Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)

2022-06-27 23:30:00

Astellas Pharma Inc. and Sutro Biopharma, Inc. announced a worldwide, strategic collaboration and licensing agreement focused on the discovery and development of novel immunostimulatory antibody-drug conjugates (iADCs). The collaboration leverages the unique cancer-fighting potential of iADCs as a novel modality, enabled by Sutro's ability to engineer complex conjugated antibodies, and Astellas' global oncology R&D expertise. This strategic partnership will engage in the development of iADCs, a next generation modality with the potential for effective and efficient approaches for treatment of cold tumors so as to bring new drug therapies to patients who do not respond to existing therapies. An iADC, which combines an antibody with a small molecule compound that induces immunogenic cell death in addition to an immune activating molecule, has the potential to boost the anti-cancer action. This partnership will enable Astellas and Sutro to mutually leverage strengths in their respective fields to accelerate iADC development for three distinct biological targets; Sutro will engage in research and preclinical studies to identify candidate compounds and then Astellas will pursue clinical development. Sutro has advanced technologies for linking drugs to antibodies and proprietary component parts, including candidate antibodies and linkable cytotoxins and immunostimulatory molecules. For development of iADCs, Astellas will utilize the strength of its global R&D and commercialization capabilities in the area of antibodies and the small molecular components. These iADCs may have the potential to provide new therapeutic options for treatment of cancers for which no broadly effective therapy is currently available. Under the terms of the agreement, Sutro will receive an upfront cash payment of USD 90 million to develop iADCs for three biological targets and may be eligible to receive up to USD 422.5 million in development, regulatory and commercial milestones for each product candidate, and tiered royalties ranging from low double-digit to mid-teens on worldwide sales of any commercial products that may result from the collaboration, subject to Sutro's cost and profit sharing option for the United States. Sutro has the option to share in the costs and profits for developing and commercializing product candidates in the United States. If Sutro exercise this option for a particular product candidate, Astellas and Sutro will equally share the costs of such co-development and co-commercialization, with the resulting profits/losses from co-commercialization also shared equally in the United States.

Negative

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell Small Cap Comp Growth Index

2022-06-24 00:00:00

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell Small Cap Comp Growth Index

Negative

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell 3000 Growth Index

2022-06-24 00:00:00

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell 3000 Growth Index

Negative

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell 2000 Growth Index

2022-06-24 00:00:00

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell 2000 Growth Index

Negative

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell 3000E Growth Index

2022-06-24 00:00:00

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell 3000E Growth Index

Negative

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell Microcap Growth Index

2022-06-24 00:00:00

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell Microcap Growth Index

Negative

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell 2500 Growth Index

2022-06-24 00:00:00

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell 2500 Growth Index

Negative

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from S&P Biotechnology Select Industry Index

2022-06-11 00:00:00

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from S&P Biotechnology Select Industry Index

Neutral

Sutro Biopharma, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 08:00 AM

2022-05-19 05:18:00

Sutro Biopharma, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 08:00 AM. Venue: Marriott Marquis, New York City, New York, United States. Speakers: Bill Newell, Chief Executive Officer.

Neutral

Sutro Biopharma, Inc. Presents at Berenberg Emerging Biotech Conference 2022, May-19-2022

2022-05-12 11:59:00

Sutro Biopharma, Inc. Presents at Berenberg Emerging Biotech Conference 2022, May-19-2022 .

Neutral

Sutro Biopharma, Inc. Presents at The JMP Securities Life Sciences Conference 2022, Jun-16-2022 09:30 AM

2022-05-02 15:24:00

Sutro Biopharma, Inc. Presents at The JMP Securities Life Sciences Conference 2022, Jun-16-2022 09:30 AM. Venue: Lotte New York Palace, 455 Madison Ave., New York City, New York, United States. Speakers: Bill Newell, Chief Executive Officer.

Neutral

Sutro Biopharma, Inc. - Shareholder/Analyst Call

2022-04-25 10:05:00

AGM

Neutral

Sutro Biopharma, Inc., Annual General Meeting, Jun 06, 2022

2022-04-25 10:05:00

Sutro Biopharma, Inc., Annual General Meeting, Jun 06, 2022, at 08:00 Pacific Standard Time. Agenda: To elect four Class I directors, each to serve three-year terms through the third annual meeting of stockholders following this meeting and until a successor has been elected and qualified or until earlier resignation or removal; to ratify the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2022; to approve, on a non-binding advisory basis, the compensation of the company’s named executive officers as disclosed in the proxy statement for the 2022 Annual Meeting; and to consider other matters.

Neutral

Sutro Biopharma, Inc. Presents at PEGS Boston Conference 2022, May-05-2022 09:00 AM

2022-04-23 07:37:00

Sutro Biopharma, Inc. Presents at PEGS Boston Conference 2022, May-05-2022 09:00 AM. Venue: Boston, Massachusetts, United States. Speakers: Arturo M. Molina, Chief Medical Officer.

Positive

Sutro Biopharma, Inc. Presents Nonclinical Data for Antibody-Drug Conjugate STRO-002 at the AACR Annual Meeting 2022

2022-04-08 17:00:00

Sutro Biopharma, Inc. announced new nonclinical data for its folate receptor alpha (FolRa) targeting antibody-drug conjugate (ADC) STRO-002, in an e-poster session, at the American Association for Cancer Research (AACR) Annual Meeting 2022, being held virtually and in New Orleans from April 8-13, 2022. STRO-002 is an ADC designed to target FolRa, which is currently in Phase 1 clinical trials for the treatment of ovarian and endometrial cancers. In the e-poster session presented at AACR, studies in vitro demonstrate STRO-002's ability to induce hallmarks of immunogenic cell death. Studies in vivo show that pre-administration of STRO-002 to FolRa-expressing tumor cells confers anti-tumor immunity as demonstrated by both rejection of the primary tumor and significant protection after a tumor re-challenge. Further, in vivo induction of immunogenic cell death extended to a complementary anti-tumor mechanism in combination with a checkpoint inhibitor (avelumab) in re-challenged animals. Additionally, when STRO-002 was administered in combination with an anti-VEGF antibody (bevacizumab), the tumor growth was significantly inhibited. Nonclinical studies using endometrial and non-small cell lung cancer (NSCLC) patient derived xenograft models with diverse levels of FolRa expression demonstrated robust STRO-002 activity, with the degree of efficacy correlating with FolRa levels. Similar activity was also seen in cells with moderate to low levels of FolRa expression. In the NSCLC model, a STRO-002 dose of 10 mg/ml resulted in significant and long-term responses.

Neutral

Sutro Biopharma, Inc. Presents at AACR Annual Meeting 2022, Apr-08-2022 12:00 PM

2022-04-08 16:09:00

Sutro Biopharma, Inc. Presents at AACR Annual Meeting 2022, Apr-08-2022 12:00 PM. Venue: Ernest N. Morial Convention Center, New Orleans, Louisiana, United States.

Neutral

Joh. Berenberg, Gossler & Co. KG, Berenberg Emerging Biotech Conference 2022, May 19, 2022

2022-04-08 04:47:00

Joh. Berenberg, Gossler & Co. KG, Berenberg Emerging Biotech Conference 2022, May 19, 2022.

Neutral

Sutro Biopharma, Inc. Presents at World ADC Europe 2022, Mar-29-2022 through Apr-01-2022

2022-04-01 16:18:00

Sutro Biopharma, Inc. Presents at World ADC Europe 2022, Mar-29-2022 through Apr-01-2022. Presentation Date & Speakers: Mar-29-2022, Trevor J. Hallam, President of Research & Chief Scientific Officer. Mar-30-2022, Arturo M. Molina, Chief Medical Officer.

Neutral

Sutro Biopharma, Inc. Presents at 12th Annual World ADC Conference 2022, Mar-29-2022 through Mar-31-2022

2022-03-30 09:20:00

Sutro Biopharma, Inc. Presents at 12th Annual World ADC Conference 2022, Mar-29-2022 through Mar-31-2022. Venue: London, United Kingdom. Presentation Date & Speakers: Mar-29-2022, Trevor J. Hallam, President of Research & Chief Scientific Officer. Mar-30-2022, Arturo M. Molina, Chief Medical Officer.

Neutral

Sutro Biopharma, Inc. Presents at Wells Fargo Annual Biotech Forum, Apr-12-2022

2022-03-29 20:00:00

Sutro Biopharma, Inc. Presents at Wells Fargo Annual Biotech Forum, Apr-12-2022 . Venue: Miami, Florida, United States. Speakers: Annie J. Chang, Vice President of Investor Relations, Edward C. Albini, CFO & Secretary, William J. Newell, CEO & Director.

Neutral

Hanson Wade Limited, 12th Annual World ADC Conference 2022, Mar 29, 2022 through Mar 31, 2022

2022-03-29 17:52:00

Hanson Wade Limited, 12th Annual World ADC Conference 2022, Mar 29, 2022 through Mar 31, 2022. Venue: London, United Kingdom.

Neutral

Wells Fargo Securities, LLC, Wells Fargo Annual Biotech Forum, Apr 12, 2022 through Apr 13, 2022

2022-03-29 11:02:00

Wells Fargo Securities, LLC, Wells Fargo Annual Biotech Forum, Apr 12, 2022 through Apr 13, 2022. Venue: Miami, Florida, United States.

Neutral

Sutro Biopharma, Inc. Presents at Needham 21st Annual Healthcare Conference, Apr-14-2022 03:00 PM

2022-03-04 13:30:00

Sutro Biopharma, Inc. Presents at Needham 21st Annual Healthcare Conference, Apr-14-2022 03:00 PM. Speakers: Bill Newell, Chief Executive Officer.

Neutral

JMP Securities LLC, the JMP Securities Life Sciences Conference 2022, Jun 15, 2022 through Jun 16, 2022

2022-02-16 16:45:00

JMP Securities LLC, The JMP Securities Life Sciences Conference 2022, Jun 15, 2022 through Jun 16, 2022. Venue: Lotte New York Palace, 455 Madison Ave., New York City, New York, United States.

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.

Neutral

Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022

2022-02-11 23:04:00

Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022.

Neutral

American Association For Cancer Research, AACR Annual Meeting 2022, Apr 08, 2022 through Apr 14, 2022

2022-01-13 18:45:00

American Association For Cancer Research, AACR Annual Meeting 2022, Apr 08, 2022 through Apr 14, 2022. Venue: Ernest N. Morial Convention Center, New Orleans, Louisiana, United States.

Neutral

Cambridge Innovation Institute, LLC, PEGS Boston Conference 2022, May 02, 2022 through May 06, 2022

2022-01-13 18:45:00

Cambridge Innovation Institute, LLC, PEGS Boston Conference 2022, May 02, 2022 through May 06, 2022. Venue: Boston, Massachusetts, United States.

Neutral

Sutro Biopharma, Inc. Enters into Licensing Agreement with Tasly Biopharmaceuticals Co., Ltd. to Grant Tasly an Exclusive License to Develop and Commercialize Stro-002 in Greater China, Consisting of China, Hong Kong, Macau and Taiwan

2021-12-27 12:01:00

On December 24, 2021, Sutro Biopharma, Inc. entered into a licensing agreement with Tasly Biopharmaceuticals Co., Ltd. (“ Tasly ”), to grant Tasly an exclusive license to develop and commercialize STRO-002 in Greater China, consisting of China, Hong Kong, Macau and Taiwan. Tasly will pursue the clinical development, regulatory approval, and commercialization of STRO-002 in multiple indications, including ovarian cancer, non-small cell lung cancer, triple-negative breast cancer, and other indications in Greater China. The Company will retain development and commercial rights of STRO-002 globally outside of Greater China, including the United States. Under the Tasly License Agreement, Tasly will make to the Company an initial payment of $40 million, with potential payments totaling up to $345 million related to development, regulatory and commercialization milestones. The Company will provide STRO-002 to Tasly under appropriate clinical and commercial supply service agreements. Upon commercialization, the Company will receive tiered, low- to mid-teen royalties based on annual net sales of STRO-002 in Greater China for at least ten years following the first commercial sale of STRO-002 in Greater China. Tasly has the right to terminate the Tasly License Agreement for convenience or other reasons specified in the Tasly License Agreement, upon prior written notice.

Neutral

Sutro Biopharma, Inc. - Special Call

2021-12-27 12:00:00

To Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program STRO-002 for Treatment of Advanced Ovarian Cancer

Neutral

Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China

2021-12-27 12:00:00

Sutro Biopharma, Inc. announced an exclusive license agreement with Tasly Biopharmaceuticals Co. Ltd. for the development and commercialization of STRO-002 in Greater China, consisting of mainland China, Hong Kong, Macau and Taiwan. STRO-002 is a FolRa-targeting antibody-drug conjugate (ADC), currently in clinical studies for patients with ovarian and endometrial cancers in the U.S. and Europe. Under the terms of the agreement, Sutro will receive an upfront payment of $40 million and be eligible to receive potentially up to $345 million in development and commercial milestone payments. Tasly will pursue the clinical development, regulatory approval, and commercialization of STRO-002 in Greater China for ovarian and endometrial cancers, with the potential to expand to further oncological indications including non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). Sutro retains development and commercial rights of STRO-002 outside of Greater China. Sutro will be responsible for the clinical trial and initial commercial supply of STRO-002 for trials in the licensed territory pursuant to a supply agreement according to customary terms. Upon commercialization, Sutro will receive tiered, double-digit royalties based on annual net sales of STRO-002 in Greater China.

Positive

Sutro Biopharma, Inc. Announces Company Kol Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program Stro-002 for Treatment of Advanced Ovarian Cancer

2021-12-27 12:00:00

Sutro Biopharma, Inc. announced that it will provide interim data from the Company's ongoing dose-expansion cohort of the Phase 1 study of STRO-002, a folate receptor alpha (FolRa) targeting antibody-drug conjugate (ADC), for patients with advanced ovarian cancer, at a Company hosted KOL virtual event. The event and Q&A session will be available by webcast, to be held on Jan. 5, 2022, at 5 pm ET, or 2 pm PT. The Phase 1 dose-expansion cohort includes advanced ovarian cancer patients with progressive disease, who had previously received up to three lines of therapy, and is open to patients who have not been selected on the basis of FolRa-expression. The study had a target enrollment of 40 patients, with the first patient dosed in January 2021 and completed enrollment with 44 patients in November 2021. The data will be presented by Sutro management and Dr. R. Wendel Naumann, Principal Investigator in the STRO-002-GM1 studies. Dr. Naumann is a professor and Director of Gynecologic Oncology Research and Associate Medical Director of Clinical Trials at the Levine Cancer Institute, Atrium Health in Charlotte, North Carolina. Dr. Naumann is also a member of Sutro's Clinical Advisory Board.

Positive

Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present At American Society of Hematology Annual Meeting 2021

2021-12-13 12:00:00

Sutro Biopharma, Inc. announced that its research collaborators at the Fred Hutchinson Cancer Research Center presented nonclinical data of STRO-002 and STRO-001 in two oral presentations at the 63rd American Society of Hematology Annual Meeting in Atlanta, Georgia. The research was conducted by investigators from the laboratory of Soheil Meshinchi, M.D., Ph.D., Professor, Clinical Research Division at Fred Hutchinson Cancer Research Center and Professor, Division of Pediatric Hematology-Oncology at the University of Washington School of Medicine. Nonclinical data was presented by Quy Le, Ph.D., Staff Scientist, Meshinchi Lab, Fred Hutchinson Cancer Research Center on Sutro's folate receptor alpha (FOLR1 or FolRa) -targeting antibody-drug conjugate, STRO-002, as a potential therapeutic in a rare pediatric acute myeloid leukemia subtype expressing FolRa. RNA-sequencing data demonstrated that FOLR1 is uniquely expressed in CBFA2T3-GLIS2 fusion (CBF/GLIS) AML and absent in other AML subtypes and normal hematopoietic cell populations. Data from an AML cell line engineered to express FOLR1 and CBF/GLIS-transduced cord blood hematopoietic stem/progenitor cells (CB HSPCs) demonstrated high cytotoxicity of STRO-002. In FOLR1 positive and CBF/GLIS-transduced CB HSPCs xenograft models, STRO-002 demonstrated potent activity that led to complete leukemia clearance. Nonclinical data was also presented by Quy Le, Ph.D., Staff Scientist, Meshinchi Lab, Fred Hutchinson Cancer Research Center on Sutro's CD74-targeting ADC, STRO-001, as a potential therapeutic in AML and acute lymphoblastic leukemia (ALL). Data from AML and ALL cell lines, as well as from nonclinical xenograft models, demonstrated robust in vitro and in vivo cytotoxicity of STRO-001 on cells expressing high- to -moderate levels of CD74, with no cytotoxicity observed in cells without CD74 expression. Potent anti-leukemia activity was also demonstrated in three primary AML patient samples with varied CD74 expression levels.

Neutral

Sutro Biopharma, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021

2021-11-22 15:06:00

Sutro Biopharma, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.

Neutral

Sutro Biopharma, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM

2021-11-19 20:08:00

Sutro Biopharma, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM. Speakers: Bill Newell, Chief Executive Officer.

Negative

Sutro Biopharma, Inc. Announces Appointment of Heidi Hunter to Board of Directors, Member of the Audit Committee and Science and Technology Committee, Effective as of November 19, 2021

2021-11-17 12:00:00

Sutro Biopharma, Inc. announced that Heidi Hunter has been appointed to the company's Board of Directors. Heidi Hunter has over 25 years of experience in biotech across the pharmaceutical value chain, from clinical and commercial development through to launch execution. She is currently President at Cardinal Health, where she leads the Specialty Solutions Business. Prior to Cardinal Health, Ms. Hunter was Senior Vice President of the Global Immunology Business Unit at UCB in Brussels. The company appointed Heidi Hunter as Class I director, member of the Audit Committee and Science and Technology Committee, effective as of November 19, 2021.

Neutral

Hanson Wade Limited, World ADC Europe 2022, Mar 29, 2022 through Apr 01, 2022

2021-11-09 17:12:00

Hanson Wade Limited, World ADC Europe 2022, Mar 29, 2022 through Apr 01, 2022.

Neutral

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021

2021-10-25 10:00:00

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.

Neutral

Sutro Biopharma, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 10:05 AM

2021-10-22 14:50:00

Sutro Biopharma, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 10:05 AM. Speakers: Bill Newell, Chief Executive Officer.

Neutral

Sutro Biopharma, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM

2021-10-21 02:25:00

Sutro Biopharma, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom. Speakers: Bill Newell, Chief Executive Officer.

Neutral

Sutro Biopharma and BioNova Pharmaceuticals Enter into Collaboration for STRO-001 in Greater China

2021-10-12 11:00:00

Sutro Biopharma, Inc. and BioNova Pharmaceuticals Limited jointly announced an option agreement for BioNova to develop and commercialize STRO-001, a CD74-targeting Antibody-Drug Conjugate (ADC), for patients with hematologic cancers, in Greater China, including mainland China, Hong Kong, Macau and Taiwan. Under the terms of the agreement, BioNova has the option to obtain exclusive rights to develop and commercialize STRO-001 in Greater China. BioNova will pursue the clinical development, regulatory approval, and commercialization of STRO-001 in multiple indications, including non-Hodgkin's lymphoma, multiple myeloma, and leukemia in the licensed territory. Sutro will retain development and commercial rights of STRO-001 globally outside of Greater China, including the United States. BioNova will pay to Sutro an initial licensing option payment of $4 million, with potential payments totaling up to $200 million related to option exercise, development, regulatory, and commercial milestones. Sutro will provide STRO-001 to BioNova under appropriate clinical and commercial supply service agreements. Upon commercialization, Sutro will receive tiered, double-digit royalties based on annual net sales of STRO-001 in Greater China.

Neutral

Sutro Biopharma, Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-10-2021 04:20 PM

2021-10-01 10:34:00

Sutro Biopharma, Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-10-2021 04:20 PM. Venue: Rancho Palos Verdes, California, United States. Speakers: William J. Newell, CEO & Director.

Neutral

Sutro Biopharma Announces Extension of Cytokine Derivative Research Program Under Collaboration with Merck

2021-09-30 11:00:00

Sutro Biopharma, Inc. announced that Merck, known as MSD outside the United States and Canada, has extended the research term for the first cytokine derivative program under the 2018 Merck Agreement, for an additional two years. The research extension is intended to facilitate completion of preclinical research and development activities for a second candidate, which has a novel design and approach. As part of this extension, Sutro is eligible to receive up to $10 million.

Neutral

Sutro Biopharma, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-15-2021 01:20 PM

2021-09-28 21:20:00

Sutro Biopharma, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-15-2021 01:20 PM. Venue: New York, New York, United States. Speakers: Bill Newell, Chief Executive Officer.

Negative

Sutro Biopharma, Inc. Announces Management Changes

2021-09-16 11:00:00

Sutro Biopharma, Inc. announced the appointment of two executives to the company's leadership team. Nicole M. Chieffo, MBA, has joined as Vice President of Clinical Operations and Werner Rubas, Ph.D., has joined as Vice President of Preclinical Development. Nicole Chieffo has over 25 years of clinical operations and development experience. Nicole joins Sutro from Janssen Pharmaceuticals where she previously held Sr. Director, Oncology Global Operations Head and Lead Oncology Clinical Scientist positions. Nicole worked directly with Janssen's medical oncology and hematology physician team leaders in advancing the Early and Late-Stage Research and Development portfolio. Formerly, Dr. Rubas was at Nektar Therapeutics for over nine years, most recently as Executive Director in Non-Clinical Pharmacokinetics and Pharmacodynamics. At Nektar he provided leadership support, directed the generation of data packages for regulatory submissions of NKTR-214, NKTR-358, NKTR-262 and NKTR-255, filed a patent application for an immunotherapeutic tumor treatment method, and provided scientific input on cross-functional teams from research concepts to late stage development.

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Positive

Sutro Biopharma, Inc. Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer

2021-08-18 11:00:00

Sutro Biopharma, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for STRO-002, a folate receptor alpha (FolRa)-targeting antibody-drug conjugate (ADC), for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of systemic therapy.

Negative

Sutro Biopharma, Inc. Announces the Appointment of Jane Chung to the Newly-Created Position of Chief Commercial Officer, Effective August 9, 2021

2021-08-09 11:00:00

Sutro Biopharma, Inc. announced the appointment of Jane Chung to the newly-created position of Chief Commercial Officer, effective August 9, 2021. Ms. Chung will provide patient, provider, thought leader, and reimbursement insights as Sutro's clinical programs advance. Ms. Chung will envision and lead an emerging commercial focus within Sutro, including engagement of the various oncology communities and stakeholders as well as planning for sales, marketing, and market access functions for the company. Ms. Chung has more than 20 years of pharmaceutical and biotechnology experience, most recently having served as President of AstraZeneca Canada, as well as previous roles at Onyx Pharmaceuticals and Genentech and is a registered pharmacist.

Neutral

Sutro Biopharma, Inc. has filed a Shelf Registration in the amount of $13.905 million.

2021-08-06 00:00:00

Sutro Biopharma, Inc. has filed a Shelf Registration in the amount of $13.905 million. Security Name: Common Stock Securities Offered: 750,000 Transaction Features: ESOP Related Offering

Neutral

Sutro Biopharma, Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-09-2021 03:20 PM

2021-07-22 14:24:00

Sutro Biopharma, Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-09-2021 03:20 PM. Speakers: William J. Newell, CEO & Director.

Neutral

Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021

2021-07-22 09:08:00

Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021.

Neutral

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021

2021-07-08 08:44:00

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New York, United States.

Neutral

Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021

2021-06-29 20:28:00

Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021.

Neutral

Sutro Biopharma, Inc. Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-11-2021 02:20 PM

2021-06-29 20:28:00

Sutro Biopharma, Inc. Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-11-2021 02:20 PM. Speakers: William J. Newell, CEO & Director.

Fundamental Summary

Sutro Biopharma's financial reports for Q4 showed some underwhelming results. Specifically, their growth and value factors indicate an execution challenge when it comes to generating exciting and consistent growth. These results suggest a challenging future for Sutro Biopharma's stock. We therefore gave Sutro Biopharma a total score of 59 out of 100 and a UNDERPERFORM recommendation.

Sutro Biopharma reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was USD 5.9 million compared to USD 14.66 million a year ago. Net loss was USD 39.11 million compared to USD 30.36 million a year ago. Basic loss per share from continuing operations was USD 0.84 compared to USD 0.66 a year ago.

Business Description

Sutro Biopharma operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company’s product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma was incorporated in 2003 and is headquartered in South San Francisco, California.

Sector Overview

Sutro Biopharma is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Sutro Biopharma's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 341.4 -8.1% 69
Liabilities 88.8 1.1% 82
Price to Book 2.7 -11.4% 49
Cash & Equivalents 30.4 -1.0% 66
Equity 252.6 -10.9% 56
EBITDA -83.0 -18.7% 47
Total Revenues 61.9 4.0% 60
Parameter Value Change Score
Return on Equity -36.1 25.0% 80
Net Cashflow -175.7 -422.1% 83
Capital Expenditure -15.3 -6.3% 64
Asset Turnover 0.2 -4.0% 50
Free Cashflow -2.1 -0.5% 67

* All values are TTM

The below chart reflects Sutro Biopharma's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Sutro Biopharma's peer average final assessment score stands on 62.0, Sutro Biopharma's score is 59.

  •  STRO
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 0 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 1 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 2 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 3 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 4 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 5 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 6 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 7 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 8 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 9 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 10 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 11 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 12 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 13 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 14 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 15 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 16 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 17 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 18 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 19 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 20 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 22 1
Amgen Inc. 130.1B 69 78 81
Hold
77
77 23 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 24 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 26 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 27 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 28 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 30 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 31 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 32 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 33 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 34 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 35 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 36 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 37 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 39 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 40 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 41 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 42 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 43 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 44 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 46 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 47 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 48 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 50 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 52 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 53 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 54 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 55 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 57 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 58 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 59 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 60 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 61 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 62 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 65 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 66 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 69 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 70 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 71 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 72 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 73 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 74 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 75 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 76 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 77 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 78 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 79 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 80 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 81 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 82 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 83 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 84 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 85 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 92 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 93 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 94 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 95 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Sutro Biopharma's stock is now priced above its 5-day and 50-day, but below its 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a positive setup in both the short and medium-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Sutro Biopharma's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 52.

Bearish 52
Close Price 5.23
52W Low 3.41
52W High 23.53
5D MA 4.45
50D MA 5.07
200D MA 11.72
MACD -0.17
RSI 0.2
STOCH 100.0

Balance Sheet Analysis

Sutro Biopharma appears likely to maintain its strong balance sheet metrics and momentum going forward. Sutro Biopharma has done an excellent job managing its liabilities. Sutro Biopharma's liabilities stood at 88.8 in the current filing, which represents a 1.1% change from the previous report. This performance is all interesting relative to their peers and suggests that their stock price has room to grow to reflect a higher intrinsic value. Therefore, we rated their liabilities movement with a score of 82. Also, The company's assets section could set high expectations for Sutro Biopharma's future attractiveness, as they went to 341.4, which is a -8.1% change from the last period. This growth should support upward pressure on its's stock price, which better captures their intrinsic value. Consequently, their asset movement received a grade of 69. That said, one metric, Book Value Factors, stood out as particularly concerning. Sutro Biopharma publishes discouraging results related to book value factors in this report. As of the current filing, price to book ratio (P/B) was reported as 2.7, representing a -11.4% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 23.0%. Their book value factor metrics are even more concerning when compared to their peers. Consequently, their book value factors movement received a grade of 49. Consequently, their balance sheet earned a rank of 61.

Parameter Value Change Score
Assets 341.4 -8.1% 69
Liabilities 88.8 1.1% 82
Price to Book 2.7 -11.4% 49
Cash & Equivalents 30.4 -1.0% 66
Equity 252.6 -10.9% 56
* All values are TTM

The below chart describes Sutro Biopharma's performance as reflected on its balance sheet with respect to its peers. While Sutro Biopharma received a balance sheet score of 61, the average of its peers stands on 63.0.

  •  STRO
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 0 1
CureVac N.V. 2.6B 49 64 75 52 52 57 1 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 2 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 3 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 4 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 5 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 6 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 7 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 8 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 9 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 10 1
CareDx, Inc 1.2B 54 67 52 39 51 52 11 1
MannKind Corporation 957.2M 79 59 50 40 64 57 12 1
Merus N.V. 941.6M 59 68 50 83 81 70 13 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 14 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 15 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 16 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 17 1
Affimed N.V. 415.0M 56 66 63 56 47 54 18 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 19 1
AC Immune SA 299.8M 84 64 47 53 75 68 20 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 22 1
Amgen Inc. 130.1B 72 68 86 53 62 69 23 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 24 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 26 1
BioNTech SE 34.0B 75 69 64 97 73 75 27 1
Seagen Inc. 32.9B 59 68 55 43 66 61 28 1
Biogen Inc. 29.7B 57 72 92 50 76 76 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 30 1
Incyte Corporation 16.8B 71 72 95 82 79 83 31 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 32 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 33 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 34 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 35 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 36 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 37 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 38 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 39 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 40 1
Alkermes plc 5.0B 63 66 46 54 71 62 41 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 42 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 43 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 44 1
Natera, Inc. 3.6B 73 65 43 95 42 54 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 46 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 47 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 48 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 50 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 52 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 53 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 54 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 55 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 57 1
Vericel Corporation 1.1B 51 65 56 53 61 57 58 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 59 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 60 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 61 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 62 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 63 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 65 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 66 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 69 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 70 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 71 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 72 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 73 1
Geron Corporation 566.2M 69 72 37 59 62 60 74 1
Immatics N.V. 538.7M 56 70 84 95 73 76 75 1
Agenus Inc. 520.5M 73 62 37 55 60 54 76 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 77 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 78 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 79 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 80 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 81 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 82 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 83 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 84 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 85 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 92 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 93 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 94 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 95 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Sutro Biopharma's income statement report highlighted several concerning metrics. Sutro Biopharma's EBIDTA now sits at -83.0 and represents -18.7% change from the last reporting period. This metric might have a 23.8 percent impact on companies in the same industry and with the same market capitalization. The company's EBITDA metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Its EBITDA movement, therefore, received a grade of 47. Also, Sutro Biopharma's revenue efficiency metrics look especially concerning this period, highlighting issues management is having controlling and reducing expenses while increasing earnings. This metric might have a 12.9 percent impact on companies in the same industry and with the same market capitalization. Their revenue efficiency does not make a compelling case for upward pressure on the company's stock price. Consequently, their revenue efficiency received a grade of 60. However, we can draw some encouragement from Sutro Biopharma's momentum in cash_flow generation. In this filing, Sutro Biopharma reported a return on equity (ROE) ratio of -36.1, which represents a change of 25.0%. These numbers show that management has successfully encouraged growth while managing ROE and ROA metrics, especially relative to their peers. Consequently, their return factors received a grade of 80. Therefore, it received a cautionary score of 56.

Parameter Value Change Score
EBITDA -83.0 -18.7% 47
Total Revenues 61.9 4.0% 60
Return on Equity -36.1 25.0% 80
* All values are TTM

The below chart describes Sutro Biopharma's performance as reflected on its income statement with respect to its peers. While Sutro Biopharma received a income statement score of 56 , the average of its peers stands on 60.0.

  •  STRO
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 0 1
CureVac N.V. 2.6B 45 83 71 74 1 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 2 1
Abgenix Inc. 2.1B 47 47 47 47 3 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 4 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 5 1
Xencor, Inc. 1.6B 42 94 52 79 6 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 7 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 8 1
Veracyte, Inc. 1.4B 45 63 57 55 9 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 10 1
CareDx, Inc 1.2B 61 44 82 50 11 1
MannKind Corporation 957.2M 95 48 56 61 12 1
Merus N.V. 941.6M 48 60 59 54 13 1
Amarin Corporation plc 734.5M 95 44 82 63 14 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 15 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 16 1
Radius Health, Inc. 499.8M 94 71 68 82 17 1
Affimed N.V. 415.0M 95 49 75 66 18 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 19 1
AC Immune SA 299.8M 83 61 65 70 20 1
Chimerix, Inc. 178.4M 99 50 62 65 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 22 1
Amgen Inc. 130.1B 74 75 64 78 23 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 24 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 26 1
BioNTech SE 34.0B 41 89 75 79 27 1
Seagen Inc. 32.9B 54 65 70 62 28 1
Biogen Inc. 29.7B 90 57 73 70 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 30 1
Incyte Corporation 16.8B 59 77 60 73 31 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 32 1
United Therapeutics Corporation 10.6B 57 91 54 82 33 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 34 1
Exact Sciences Corporation 7.2B 57 67 54 62 35 1
Exelixis, Inc. 6.7B 54 91 54 81 36 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 37 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 39 1
Ascendis Pharma A/S 5.2B 38 68 46 54 40 1
Alkermes plc 5.0B 69 55 81 62 41 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 42 1
Novavax, Inc. 4.0B 41 89 54 75 43 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 44 1
Natera, Inc. 3.6B 52 51 78 52 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 46 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 47 1
Insmed Incorporated 2.4B 51 58 73 57 48 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 50 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 52 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 53 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 54 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 55 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 56 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 57 1
Vericel Corporation 1.1B 76 44 82 56 58 1
IVERIC bio, Inc. 1.1B 84 58 79 70 59 1
FibroGen, Inc. 1.0B 48 74 63 67 60 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 61 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 62 1
ImmunoGen, Inc. 946.1M 40 73 71 64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 65 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 66 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 68 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 69 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 70 1
CTI BioPharma Corp. 603.6M 84 50 62 59 71 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 72 1
AnaptysBio, Inc. 586.3M 97 50 77 68 73 1
Geron Corporation 566.2M 89 67 73 78 74 1
Immatics N.V. 538.7M 37 93 53 77 75 1
Agenus Inc. 520.5M 57 83 45 74 76 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 77 1
Vaxart, Inc. 440.0M 99 51 72 68 78 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 79 1
MiMedx Group, Inc. 391.5M 87 43 83 59 80 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 81 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 82 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 83 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 84 1
Zymeworks Inc. 324.7M 58 53 77 56 85 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
Precigen, Inc. 299.1M 57 87 59 79 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
bluebird bio, Inc. 288.7M 99 91 61 96 92 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 93 1
MacroGenics, Inc. 184.6M 95 56 74 71 94 1
DermTech, Inc. 165.3M 49 48 78 52 95 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Overall, Sutro Biopharma's critical cash flow metrics appear to signal strong support and a high likelihood of positive growth going forward. Sutro Biopharma presents exciting net cash flow numbers for its recent financial release, illustrated by a net cash flow of -175.7, which is a change of -422.1% from the last filing. The company is headed in the right direction regarding business priorities, exhibiting prudent net cash flow management and growth. Consequently, their net cash flow movement received a grade of 83. Also, Sutro Biopharma did a great job related to free cash flow this period, which stood at -2.1, representing a -0.5% change from the previous filing. Companies in the same industry and market capitalization are typically affected by this parameter by up to 2.8%. The company's free cash flow metrics are especially strong compared to its peers. Management seems to balance cash flow management, asset growth, and resource allocations in general. Consequently, their free cash flow movement received a grade of 67. On the other hand, Asset Turnover, jumped out as looking rather underwhelming. Asset turnover metrics during this period were surprisingly weak. Their reported asset turnover metrics of 0.2, which represents a -4.0% change from the previous report. Companies in the same industry and market capitalization are typically affected by this parameter by up to 3.2%. Their asset turnover numbers are significantly less impressive when compared to their peers and competitors. Correspondingly, their asset turnover movement received a grade of 50. Therefore, we scored its cash flow a 74.

Parameter Value Change Score
Net Cashflow -175.7 -422.1% 83
Capital Expenditure -15.3 -6.3% 64
Asset Turnover 0.2 -4.0% 50
Free Cashflow -2.1 -0.5% 67
* All values are TTM

The below chart describes Sutro Biopharma's performance as reflected on its cash flow with respect to its peers. While Sutro Biopharma received a cash flow score of 74, the average of its peers stands on 70.0.

  •  STRO
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 0 1
CureVac N.V. 2.6B 87 80 90 70 90 1 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 2 1
Abgenix Inc. 2.1B 66 53 45 59 58 3 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 4 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 5 1
Xencor, Inc. 1.6B 96 95 70 95 98 6 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 7 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 8 1
Veracyte, Inc. 1.4B 90 95 46 46 82 9 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 10 1
CareDx, Inc 1.2B 98 84 40 50 86 11 1
MannKind Corporation 957.2M 77 56 43 37 66 12 1
Merus N.V. 941.6M 70 71 74 53 71 13 1
Amarin Corporation plc 734.5M 52 40 74 55 55 14 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 15 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 16 1
Radius Health, Inc. 499.8M 64 40 37 56 57 17 1
Affimed N.V. 415.0M 72 57 95 43 74 18 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 19 1
AC Immune SA 299.8M 66 77 79 63 68 20 1
Chimerix, Inc. 178.4M 80 84 95 47 83 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 22 1
Amgen Inc. 130.1B 80 74 67 74 81 23 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 24 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 26 1
BioNTech SE 34.0B 73 97 50 52 72 27 1
Seagen Inc. 32.9B 53 53 50 87 58 28 1
Biogen Inc. 29.7B 58 54 90 73 66 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 30 1
Incyte Corporation 16.8B 78 79 92 74 84 31 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 32 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 33 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 34 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 35 1
Exelixis, Inc. 6.7B 79 90 89 83 87 36 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 37 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 38 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 39 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 40 1
Alkermes plc 5.0B 89 95 76 80 92 41 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 42 1
Novavax, Inc. 4.0B 62 38 63 54 60 43 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 44 1
Natera, Inc. 3.6B 52 54 56 84 58 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 46 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 47 1
Insmed Incorporated 2.4B 79 80 61 89 82 48 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 50 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 52 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 53 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 54 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 55 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 56 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 57 1
Vericel Corporation 1.1B 64 46 59 73 65 58 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 59 1
FibroGen, Inc. 1.0B 86 74 48 87 84 60 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 61 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 62 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 63 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 65 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 66 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 68 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 69 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 70 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 71 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 72 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 73 1
Geron Corporation 566.2M 78 68 49 81 77 74 1
Immatics N.V. 538.7M 82 95 56 99 86 75 1
Agenus Inc. 520.5M 57 43 52 77 58 76 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 77 1
Vaxart, Inc. 440.0M 72 56 53 38 65 78 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 79 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 80 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 81 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 82 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 83 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 84 1
Zymeworks Inc. 324.7M 52 65 45 83 57 85 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
Precigen, Inc. 299.1M 82 75 37 85 74 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 92 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 93 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 94 1
DermTech, Inc. 165.3M 60 51 45 86 58 95 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.